Open AccessMedicine

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.

A. Ferreri, K. Cwynarski, E. Pulczynski, M. Ponzoni, M. Deckert, L. Politi, V. Torri, C. Fox, P. Rosée, E. Schorb, A. Ambrosetti, Alexander Roth, C. Hemmaway, A. Ferrari, K. Linton, R. Rudà, M. Binder, T. Pukrop, M. Balzarotti, A. Fabbri, P. Johnson, J. Gørløv, G. Hess, J. Panse, F. Pisani, A. Tucci, S. Stilgenbauer, B. Hertenstein, U. Keller, S. Krause, A. Levis, H. Schmoll, F. Cavalli, J. Finke, M. Reni, E. Zucca, G. Illerhaus

2016.5.1Lancet Haematology

DOI: 10.1016/s2352-3026(16)00036-3

tlooto Summary

The IELSG32 trial provides a high level of evidence supporting the use of MATRix combination as the new standard chemoimmunotherapy for patients aged up to 70 years with newly diagnosed primary CNS lymphoma and as the control group for future randomised trials.

Abstract

Abstract is not available.

Citation format

FERRERI, A., et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (matrix regimen) in patients with primary CNS lymphoma: Results of the first randomisation of the international extranodal lymphoma study group-32 (IELSG32) phase 2 trial. Lancet Haematology, 2016, 3 5: e217–27.